BR9815070A - Compostos tendo efeito inibitório da cgmp-pde - Google Patents

Compostos tendo efeito inibitório da cgmp-pde

Info

Publication number
BR9815070A
BR9815070A BR9815070-7A BR9815070A BR9815070A BR 9815070 A BR9815070 A BR 9815070A BR 9815070 A BR9815070 A BR 9815070A BR 9815070 A BR9815070 A BR 9815070A
Authority
BR
Brazil
Prior art keywords
compounds
cgmp
pde
ring
inhibitory effect
Prior art date
Application number
BR9815070-7A
Other languages
English (en)
Inventor
Masayuki Ohashi
Hidemitsu Nishida
Toshiyuki Shudo
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of BR9815070A publication Critical patent/BR9815070A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: ''COMPOSTOS TENDO EFEITO INIBITóRIO DA CGMP-PDE''<D>. A presente invenção proporciona novos compostos com hetero-anel tetracíclico condensado tendo ação na inibição altamente seletiva da GMP-fosfodiesterase cíclica (aqui depois abreviada como cGMP-PDE), processos para a produção de tais compostos, agentes contendo pelo menos um de tais compostos como um ingrediente ativo e usados para prevenção e/ou tratamento de hipertensão pulmonar, doenças cardíacas isquêmicas, disfunção erétil, ou doenças contra as quais a inibição da cGMP-PDE é efetiva e intermediários úteis para a produção dos compostos com hetero-anel tetracíclico condensado. O assunto acima é obtido através dos novos compostos com hetero-anel tetracíclico condensado.
BR9815070-7A 1997-11-28 1998-11-27 Compostos tendo efeito inibitório da cgmp-pde BR9815070A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34416497 1997-11-28
PCT/JP1998/005350 WO1999028319A1 (fr) 1997-11-28 1998-11-27 NOUVEAUX COMPOSES PRESENTANT UN EFFET INHIBITEUR DE cGMP-PDE

Publications (1)

Publication Number Publication Date
BR9815070A true BR9815070A (pt) 2000-10-03

Family

ID=18367131

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815070-7A BR9815070A (pt) 1997-11-28 1998-11-27 Compostos tendo efeito inibitório da cgmp-pde

Country Status (14)

Country Link
US (1) US6476021B1 (pt)
EP (1) EP1048666A4 (pt)
KR (1) KR20010032546A (pt)
CN (1) CN1284075A (pt)
AU (1) AU746883B2 (pt)
BR (1) BR9815070A (pt)
CA (1) CA2311947A1 (pt)
HU (1) HUP0100083A3 (pt)
IL (1) IL136340A0 (pt)
MX (1) MXPA00005190A (pt)
NO (1) NO20002696L (pt)
PL (1) PL340789A1 (pt)
WO (1) WO1999028319A1 (pt)
ZA (1) ZA9810766B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1090022B1 (en) 1998-06-23 2003-08-06 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AU5204800A (en) * 1999-06-21 2001-01-09 Biochemical Pharmaceutical Factory of Zhuhai Sez, The Process for preparing sildenafil, and troche which comprises sildenafil and apomorphine
DE19954707A1 (de) * 1999-11-13 2001-05-17 Merck Patent Gmbh Imidazolverbindungen als Phosphodiesterase VII-Hemmer
WO2001068648A1 (en) * 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
NZ521386A (en) 2000-03-15 2004-06-25 Aventis Pharma Gmbh Substituted beta-carbolines with lkB-kinase inhibiting activity
AU2001255849B8 (en) 2000-04-19 2006-04-27 Lilly Icos, Llc. PDE-V inhibitors for treatment of Parkinson's Disease
US6271228B1 (en) * 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
CA2470210A1 (en) * 2001-12-17 2003-06-26 Altana Pharma Ag Use of selective pde5 inhibitors for treating partial and global respiratory failure
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
US8133903B2 (en) 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
US7601856B2 (en) * 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators
US7662831B2 (en) * 2006-07-27 2010-02-16 Wyeth Llc Tetracyclic indoles as potassium channel modulators
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN115872991A (zh) * 2021-09-26 2023-03-31 深圳大学 β-咔伯啉生物碱类化合物及其药用组合物、制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS261338B1 (cs) * 1987-09-17 1989-06-15 Viktor Zikan Způsob přípravy 10-nitro-4-oxo-4H-chino/2,3,4-i,j//1,4/benzoxazinových derivátů
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
PH31122A (en) * 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
JPH0710843A (ja) * 1993-03-31 1995-01-13 Eisai Co Ltd 含窒素縮合複素環化合物
ES2224130T3 (es) * 1994-08-09 2005-03-01 Eisai Co., Ltd. Compuesto de piridazina condensada.
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
JP3713783B2 (ja) * 1995-01-20 2005-11-09 大正製薬株式会社 １Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体
WO1997045427A1 (fr) * 1996-05-31 1997-12-04 Mochida Pharmaceutical Co., Ltd. DERIVES DE PYRIDOCARBAZOLE AYANT UN EFFET INHIBITEUR DE cGMP-PDE
CN1309561A (zh) * 1997-05-29 2001-08-22 持田制药株式会社 勃起机能障碍治疗剂
WO1999026946A1 (fr) * 1997-11-26 1999-06-03 Mochida Pharmaceutical Co., Ltd. DERIVES DE PYRIDOCARBAZOLE A ACTIVITE INHIBITRICE SUR LA cGMP-PDE

Also Published As

Publication number Publication date
AU1261799A (en) 1999-06-16
US6476021B1 (en) 2002-11-05
MXPA00005190A (es) 2002-04-24
ZA9810766B (en) 1999-05-25
EP1048666A1 (en) 2000-11-02
HUP0100083A3 (en) 2002-01-28
IL136340A0 (en) 2001-05-20
HUP0100083A2 (hu) 2001-08-28
NO20002696D0 (no) 2000-05-26
CA2311947A1 (en) 1999-06-10
KR20010032546A (ko) 2001-04-25
WO1999028319A1 (fr) 1999-06-10
PL340789A1 (en) 2001-02-26
AU746883B2 (en) 2002-05-02
NO20002696L (no) 2000-07-24
EP1048666A4 (en) 2001-10-31
CN1284075A (zh) 2001-02-14

Similar Documents

Publication Publication Date Title
BR9815070A (pt) Compostos tendo efeito inibitório da cgmp-pde
EA200200208A1 (ru) Синергитическая композиция
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
EA200201262A1 (ru) Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
BR0111980A (pt) Amina substituìda, composto protegido, métodos para tratar um paciente que tenha ou para prevenir que um paciente contraia uma doença ou condição, para inibir a atividade da beta-secretase, para inibir a clivagem da proteìna precursora de amilóide (app), para inibir a produção do peptìdeo beta amilóide (a beta) em uma célula, para inibir a produção de placa beta0amilóide em um animal, e para tratar ou prevenir uma doença compreendendo depósitos de beta-amilóide no cérebro, composição método para produzir um complexo de beta-secretase, conjunto, e, uso de amina substituìda
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
ATE452640T1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
BR9809508A (pt) Agente terapêutico para disfunção de ereção
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
LU90969I2 (fr) Compositions ophtalmiques topiques contenant olopatadine destinees au tritement d&#39;affections allergiques des yeux
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
KR950031059A (ko) 골다공증 치료용 약제학적 조성물
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
ATE236156T1 (de) Pyridocarbazol derivate die einen cgmp-pde inhibilierenden effekt haben
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
IS8096A (is) Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum
ATE295183T1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
DE60211746D1 (de) Aminosäurederivate zur behandlung der alzheimer-krankheit
KR950016760A (ko) 치질 치료제
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.